Today we are going to be talking about the top seven penny stocks that will be spiking in May Twenty nineteen. Now, the reason that I could say this confidently and undeniably is because the companies on this list literally tell you the exact date at which price changing events will occur. They do this by releasing FDA approval dates, face trial data releases, as well as dropping many hits and clues such as with insider trading activity now I've released a Penny Stocks of the Month video every single month since December and if you look back at the 30 or so stocks that I've covered, nearly every single one of them has provided the price action that we need to trade off of. now.

with that being said, these are not stocks that you just buy and randomly hold. These are stocks that you buy with a plan to take advantage of the short-term fluctuations. While I do recommend behind these thoughts, at certain points, your entry and exit points will make or break your position I Know Shocking. but in any case, don't do it alone.

If you need any help, we have a bunch of tutorials links in the description below to get you started on that and if you have more questions, you could always reach out to us below or on the Zipp Trader circle Facebook group. Anyways, you know a lot of work goes into researching these stocks and all I ask from you and returns to this video is that you hit that beautiful and ravishing like button. And also don't forget to subscribe if you see value in the following video. So PG and X will be presenting their phase 2 & 3 data on May 6.

Now as we know, phase data presentations could be a beautiful and wonderful time for undervalued positions. By the way, I'm going to be using the Weeble broker for this video. It's a commission free broker that was made specifically for traders, not just beginning investors. If you want to check it out, they are running a promotion right now where if you sign up with our affiliate link below, you will get a free stock.

That being said, feel free not to use our link, but I do recommend using a link back to PGX. So fundamentally speaking for those unfamiliar with the company PG and X or pro Jetix Forma is in the arena of radio form of companies that are using radiation technology to target and treat specific tumors. Now, we don't need to know much about that specifically, but we do need to know that this is a hot sector. In terms of investor speculation, there's a lot of potential profitability now.

The monkeys are pretty happy with the stock as well. They are rating it at a target price of a little over $10 on average with the Laura and hanging around 6.50 cents which is still a decent amount of upside now. Obviously I don't care much for the analysts opinions, but this is nice to have because a lot of the sheep investors. These investors that are sheep will generally feel more protected if the analysts have a higher price target.

Since the Sheep feels safer, we'll have safer levels of support and they won't sell out as easily. But moreover, if there's good news and the price starts rising, it'll bring more investors in because people are more confident. So a quick run on the balance sheet. PGX reported revenue of three dollars and twenty four cents in Q4 of 2018.

But despite that two share price finish that day and the green as investors were left unfazed and bullish on the stock. It was down about 50% in terms of expectations, but investors remain bullish on the stock. They still believed in the long-term viability of the product. Now, the real bazooka with this stock is 100% 100% On the technical side, we see a huge amount of upward potential in comparison to a relatively low amount of downward potential and honestly a pretty flat price action on the ear.

That means that if we are seeing confirmation if an uptrend, we potentially have four dollars or so of Upside and only about a dollar of downside. Now that being said, they are selling a bit too high at the moment and as you know for the ideal position, you're going to want to make sure that you are at least getting in at least below fair value on the RSI. Now the reason for this is because we need to build the largest margin for error as possible so that we can minimize our exposure to risk and maximize the potential for reward. The next one is NVR V Dow N BR V will have their PDUFA decision aka their FDA approval decision on April 30th, 2019.

Now, this obviously is not in May, but there is no doubt that we will see some of the effects of this in the first few days of May as well. Now, this drug is for urinary tract infections and as we know, drugs that may get to this stage in the process have an 80% probability of being passed based on previous statistics released by the FDA Now, NVR V also has upward potential all the way to $12 conservatively speaking, and it also has a history of spiked ability with massive intraday spikes on positive news events. Monkeys are giving it a price target at about $9.50 but anyways, this should be a big play at the end of April and early May, but since it's technically not in May I didn't include it in the overall number. Account for this video.

Okay, so Ovi D will be starting their phase 3 trial this upcoming order, but more importantly, we'll be releasing an abstract for it on May. 3rd, they will also be presenting their phase 2 data on May 7th. Now, the key with this is that company actions towards potentially lucrative new products tend to step up some sort of investor excitement and investors tend to be optimistic at the early stages of trials. At the same time, Ovid had already took a massive hit back in August when they originally revealed the Phase 2 data that they are going to be presenting on May 7th.

Now, the key with this is that Biopharma Presentations offer companies that opportunity that they need to spin the phase data in a way that shows future profitability of the underlying asset or the underlying product. In this case, the company can highlight how Ovie 101 demonstrated a statistically significant effect compared to the Placebo within that trial, But the key is that presentations tend to be very effective and standing up investor interest in the short run, and this, combined with another phase trial started in the second quarter of 2019 will likely lead to the volatility that we need to trade off of. Now if only we could figure out what the insiders think about the company. Oh hey, Charlie we can we have two fairly large acquisitions of more shares from insiders within the company as late as February These company officers obviously feel that the shares are discounted enough or they wouldn't be taking a position because they're not required to buy more shares.

That being said, this is just one more sign in the right direction. Um, one more thing that I should mention is that every time I make a video on penny stocks and include ones that have low volume I Get a lot of people that comment and they're frustrated with me. A common comment would be like Charlie you dumb dog I Don't trade low volume penny stocks I Don't look at low volume penny stocks I have nothing to do with low volume penny stocks and I understand that. But what you don't understand is the fact that when these news releases come out, volume goes up substantially.

This is because news releases often result in a flood of new investors as well as old investors flooding back into the market. If you'd like more information on volume and why, low average volume isn't necessarily bad I made a video on that I think a couple months ago and I'll put a link in the description to that. Okay, so A Do X Announced their phase 3 initiation back on April 2nd and they will be presenting the results of the phase 2 data that they did on May 1st for their drug for dry eye syndrome. Now a deal X meets one of my most important prereqs for a bio farmer or biotech penny stocks and that is this likeability factor.

It's extremely important for us to find a previous pattern of spiking big FDA news events and presentation because that allows us to get an idea on average of what will happen in future news events and moreover how much of a role FDA announcements play in the stocks price action. There's a lot of stocks that have FDA approvals coming up that I don't talk about specifically because they tend not to have as big of a role. That being said, we are also under fair value, which is great, but ideally we'd be able to find a position that's both under fair value and also showing signs of an uptrend. And of course, we always want to get that confirmation.

We're not just buying dead dogs on the side of the street. Also, there are some monkeys that really love the stock, even going so far as to set it at a $35 price target. But as we know monkeys will be monkeys now. a CH N will be releasing their phase two interim data on May 17th.

Now a CH N handed early investors around a 68% loss. But the stock has consistently been climbing up on the year, and the massive long-term upward potential combined with this consistent uptrend pattern makes me feel extremely hopeful. We have an upward potential from about 293 to 1006 or so. And also that mentioned consistent upward trend pattern, which is great.

First off, that has a phase two data release coming out mid-may As we know, shares tend to run in anticipation or in grievance before a major phase data release or FDA results, so this is excellent. PR Ers will be releasing their phase 1 initial data on May 22nd. Monkeys are rating them at a seven dollar and fifty cents price target, which is a bit excessive without knowing how the trials will go, but nonetheless they are especially considering long term resistance is at 585. Nonetheless, we are at oversold and I'd be watching to see those early warning signs in anticipation and especially getting closer to announcement day.

Phase 1 data releases can be more mild as compared to the later data releases, but sometimes they can bring more attention to the company now. Ey En had a successful phase 2 & 3 trial earlier this year and they will have a detailed data presentation on May third through seventh. Now, these data presentations allow the companies an opportunity to both promote the Charles success while also highlighting the points of profitability and how that impacts the overall company going forward. Meanwhile, it also tends to garner a lot of attention in the financial media at Lee in the biotech biopharm, the part of the financial media which can bring up the volume and volatility that we look for.

But the key here is that we have a successful company presenting about their current success while also having an uptrending pattern. and it's also not too overextended when looking at the relative strengths. Fact: We are just barely over fair value. This shows that investors are already aware of the value in this point, but the con with this is that the presentation is going to have less of an effect since the stock price has already factored in a decent amount of progress.

It's also quite Findley traded, but it's worth watching for entry points due to the presentation. So a DAP will be presenting a summary of their phase 1 data on May 2nd. Now, the fun part with a DAP is that a lot of their insiders liquidated the majority of their positions at the beginning of this year, which of course is never a good sign for a company. So with a negative phase data presentation all the second pessimistic insiders and a down trending stock, you may be wondering why in God's name I Would recommend watching it.

Well in October The stock price was massively crushed after they had that negative phase data released the original one where they released the data now they're going to be present in it, but after they released the negative phase data, the stock price was absolutely beat down like a rabid dog. This ate away much of the premium that we would normally have to pay to enter this position. Now this gives us technical upward potential from current trading price at 412 to a little bit over $14 It's also trading near oversold on the longer-term RSI which gives us a little bit more margin for error. But moreover, because of the ever increasing amount of short positions, this stock will also be prone to a short squeeze if we see any semblance of the company turning this into some good piece of news or investors somehow figuring this is good news.

Now, as we know, companies love to use presentations and summary events as a way to sort of bring more coverage and more investors into this part of the market. Now, a short squeeze combined with a much higher resistance level makes this stock extremely likely to be lucrative if it does actually show that there's some sort of good news. And on the other hand, if there is a good news which a lot of people think there's not going to be, then there really isn't that much farther that the stock can go. Now, admittedly, this is one of the more speculative plays on the list, but the thing is that just a little piece of good news.

Just a little bit of somebody thinking that the presentation went well or the presentation went whatever could skyrocket the stock because of the amount out of short sellers as well as the massive discount. But I guess the real question is if a DAP will be able to spin around their failure and with that, that's really a guessing game. And while I'm not in the business of guessing games I am in the business of using price action and early warning signs as an indication for a reversal, so the key is watching for an upward confirmation as well as making sure that we get in when the setup is perfect for us. Technically speaking, we need to make sure below fair value and we need to make sure that we have that same amount of upward potential.

If we, if the stock runs up in anticipation of this event, we may not get as good of an entry point. Now see why TK will be presenting their phase 2 data on May 5th. They sort of have this huge run-up in February and early April and then it proved to be an overreaction, but it's still not trading below fair value now. I'm not going to be including COI TK in the overall count because it's technically not a penny stock.

Penny stocks There anything rated below $5 or I've kind of extended the definition to mean anything that has traded under $5 within the last three months or so, but see why TK is absolutely not a penny stock. but I wanted to include it on this list because they will be presenting their phase two data on May 5th and it's for sure worth watching. Okay, so I wanted to give you an option if you wanted to go through this yourself on how to find all these plays as well as the other plays that we don't cover in these videos because there are a lot of them. So if you want to do this research yourself, all you have to do is go to Biopharm.

But Catalyst Calm Or Biopharm Catalyst Calm. I'll put a link in the description below to that website. You can go to Catalyst Calendars and you can go to the FDA calendar. This will show you once it loads.

This will show you all of the different drugs and all the different phase trial releases that are going to be coming out in the next period or so. Now you could organize it by Catalyst date, You can organize it by stage and whatnot and you know they could. Think about this as it shows you exactly like if you're looking for FDA approvals or FDA trials or whatever. you could actually go through this and see all of the different drugs that are going to go through their FDA approval.

see. here's NPR V that we talked about earlier, But my point is that this is a really great opportunity to go and look through everything. Some of these have FDA approvals, but they're like they're not penny stock so I'm not covering them in these videos, but there's still tradable stocks if they have a spike ability factor. So that's why it's so important for you to go through these and look on your own because you're gonna be missing a lot of opportunities if you just rely solely on my videos.

I can't cover everything but I can cover you know the ones that are applicable. And also the great thing is that you know maybe you don't know what an NDA filing is. Maybe you don't know what each phase is. You could actually go and look at the FDA calendar glossary and they cover literally everything that you could possibly need to know which is really great.

Phase 1: Phase 2: Phase 3: If you want to know what an S NDA is, if you want to know what the Advisory Committee you want to know that the dates prior to review, what the difference is between you know that the FDA approval date and if it has the priority review status Does that need you to go faster? Does it not mean it's gonna go faster? You go and click that or you can go and click that and you can read all about that. There's also the different abbreviations that you should know and I don't know I Think this is a really cool thing to know and it's important to do your own due diligence and this is an easy way to do it. What I don't recommend is: I Don't think you need to sign up for their free trial or you need I Don't think you need to sign up for anything with the website. There's no reason to pay for this information.

it's all publicly available and it's all for free on this website anyways. But I guess they do sell a membership service. That makes sense, but you don't need to do that anyways. I Hope you enjoyed this guide at the end of the day.

My goal is to make you self-sufficient so it doesn't. It doesn't really help me that much. If you're just using my list, these are supposed to be foundational earning points for you and eventually you won't need me I did. Maybe you'll still be entertained and you'll come back and watch my videos, but you don't need me to be a successful trader.

you just this is supposed to be a foundational point for you anyways. I Hope this video was helpful for you if you have any questions. Don't forget to reach out to us on the Zipp Trader Circle Facebook group or comment below. We also have a free discord chat that you could reach by going to join the Facebook group and clicking the link in the top post.

We have a bunch of different sections, so regardless of the type of stocks that you enjoy trading or the type of niche that you're in you have, you can find your community there. I Also post nightly watch lists and a bunch of other things. Also, if you're having trouble learning the material or kind of keeping track of everything I Have a trading tutorials playlist that you can access by going to the zip trader homepage, clicking trading tutorials, and then working your way down. Anyways, have a great day folks and I'll see you in the next video.